Tag: EmboTrap
Combined thrombectomy technique fails to demonstrate superiority over aspiration alone
New data from the VECTOR randomised controlled trial—presented at the European Stroke Organisation Conference (ESOC; 24–26 May, Munich, Germany)—have indicated that a mechanical thrombectomy...
World-renowned clot science drives outstanding EMBOTRAP stent retriever outcomes in MASTRO...
This advertorial is sponsored by CERENOVUS.
The EMBOTRAP® family of revascularisation devices (CERENOVUS) is innovative within the stent retriever space due to its differentiated design...
Cerenovus reveals positive stent-retriever thrombectomy outcomes within EXCELLENT registry
Cerenovus, part of Johnson & Johnson MedTech, has today announced positive primary outcomes from the real-world EXCELLENT registry, focused on stroke-inducing blood clot removal...
ISC 2022: Global EXCELLENT study “shows how much stroke thrombectomy has...
Mechanical removal of blood clots reduced post-stroke disability in nearly half of “all-comer” real-world stroke patients in a global study, according to preliminary late-breaking...
First pass effect…always the goal!
Ischaemic stroke is as quick as it is destructive; minutes, even seconds can be the difference between patients returning to a healthy life or a hindered one....
New study shows use of EmboTrap device clot retriever during treatment...
A device designed to remove clots from the brain following an ischaemic stroke, the EmboTrap demonstrated high success rates in restoring blood flow and...
ARISE II results show two-thirds of ischaemic stroke patients return to...
EmboTrap (Neuravi/Johnson and Johnson’s Cerenovus) achieved a high reperfusion rate among acute ischaemic stroke patients with large vessel occlusion. With three, or fewer, passes...
Real-life use of EmboTrap shows comparable outcomes to large stroke studies
The real-life use of the EmboTrap device (Neuravi/Cerenovus) has provided “very good outcomes” when compared to that observed in large mechanical thrombectomy trials which...
Codman Neuro acquires Neuravi
Codman Neuro has announced the acquisition of Neuravi. This acquisition comes after the company’s recent acquisition of Pulsar Vascular, expanding its products for stroke...
Enrolment complete in ARISE II trial of EmboTrap device
Enrolment is now complete in the ARISE II clinical trial which is assessing the safety and effectiveness of the EmboTrap II revascularisation device (Neuravi),...
Neuravi secures €15 million to fund expansion
Neuravi has announced €15 million in venture debt financing from IPF Partners, a leading alternative financing provider focused on the healthcare sector.
This financing allows...
Neuravi announces European launch of EmboTrap II stent retriever for treatment...
Neuravi has received CE mark approval for newly available enhancements to its EmboTrap stent retriever platform, the EmboTrap II revascularisation device. The company will...
